GlassScriptPhysician profile
Khondker Islam
NPI 1568441855
$3,601.85
in general payments reported to CMS, 2019-2025
28 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2022: $246 · 2023: $109 · 2024: $474 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.27 |
| Education | $117.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.88 | 2022-2025 | |
| Janssen Biotech, INC. | $571.44 | 2024-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $233.79 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.73 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $217.45 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $190.50 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $177.76 | 2022-2025 | Entyvio |
| Pfizer INC. | $160.72 | 2019 | |
| Mallinckrodt Hospital Products INC. | $69.01 | 2024-2025 | Acthar, Terlivaz |
| Intercept Pharmaceuticals, INC. | $66.52 | 2019-2025 | |
| Genzyme Corporation | $61.50 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $60.64 | 2025 | Iqirvo |
| Ardelyx, INC. | $50.25 | 2025 | Ibsrela |
| Orphalan INC | $50.12 | 2025 | Cuvrior |
| Lilly USA, LLC | $49.99 | 2024-2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Aimmune Therapeutics, INC. | $31.97 | 2025 | Zenpep |
| Csl Behring | $17.14 | 2024 | Hizentra |
| Neurocrine Biosciences, INC. | $16.58 | 2024 | Ingrezza |
| Ferring Pharmaceuticals INC. | $14.81 | 2025 | Rebyota |
| Teva Pharmaceuticals USA, INC. | $14.30 | 2024 | Austedo Xr |
| Digestive Care, INC. | $14.26 | 2025 | Pertzye |
| Novo Nordisk INC | $13.96 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $13.92 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $13.92 | 2024 | |
| Celltrion USA INC. | $13.86 | 2025 | Vegzelma |
| Echosens North America, INC. | $11.13 | 2025 | Fibroscan |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khondker Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.